It is now accepted that there is a link between renal dysfunction and heart disease, although physiological mechanisms remain unclear. The incidence and prevalence of chronic kidney disease are increasing, and it is estimated that 26 million Americans now have chronic kidney disease. 1 From a public health standpoint, HF and chronic kidney disease are similar in that the underlying pathology is underway long before symptoms are manifested, thereby causing them to be largely underdiagnosed in their early stages. Any advance or improvement in early detection of HF or chronic kidney disease could have enormous potential to reduce the morbidity and mortality from these treatable diseases.
The Dallas Heart Study showed that serum levels of cystatin C were independently associated with LV mass, concentricity, and wall thickness as measured by MRI. 3 Male gender, hypertension, and use of antihypertensive medications were all associated with elevations of cystatin C. However, even after adjustment for these and other traditional risk factors, including estimated glomerular filtration rate (eGFR), the associations of cystatin C with a pathological cardiac phenotype persisted. These findings show that the risk of HF predicted by elevations of cystatin C is more than can be explained by its surrogacy as a predictor of impaired renal function.
Clinical inferences concerning renal filtration function have been fundamental to medical evaluation of patients for over half a century. Serum creatinine has been the laboratory mainstay measure, and cystatin C is a relatively new test available to clinicians. 4 In the past decade, there has been a large effort to use eGFR as a clinical measure derived from the serum creatinine. GFR is most commonly calculated by the modified 4-variable modification of diet in renal disease equation but can be estimated using several calculations dependent on factors that influence muscle mass and creatinine production including age, sex, and black race. [5] [6] [7] Likewise, eGFR can be calculated from a variety of cystatin C equations, which do not consider sex or proxies of muscle mass such as black race. 8 -11 The Table outlines the key differences between creatinine and cystatin C.
The limitations of serum creatinine as a blood measure reflecting renal filtration have been extensively debated. Creatinine is a low-molecular-weight (113 Da) protein derived from the breakdown of skeletal muscle creatine phosphate, which is used as an energy substrate ( Figure 1 ). Creatinine is freely filtered by the glomerulus and also undergoes a small amount of tubular secretion. Highly dependent on muscle mass, creatinine levels vary greatly among individuals who differ in age, sex, diet, and race. The first practical test for the determination of creatinine in urine, described more than 100 years ago (1886) by Max Jaffe (1841-1911), involves the formation of the redyellowish-brown-colored creatinine picrate by the bonding of picric acid and creatinine in an alkaline solution. 12 In 1936, the Benedict method of creatinine determination was reported, which involves the reaction of 3,5-dinitrobenzoic acid with creatinine in an alkaline medium. 13 From this point forward, the creatinine assay, unlike other laboratory tests, has not evolved.
Cystatin C is a 122-amino acid, 13 250-Da protein that is a member of the family of cysteine proteinase inhibitors (Figure 2 ). 14 It is the product of a "housekeeping" gene expressed in all nucleated cells and is produced at a constant rate. Because of its small size, cystatin C is freely filtered by the glomerulus. It is not secreted but is reabsorbed by tubular epithelial cells and subsequently catabolized so that it does not return to the blood flow (Table) . This latter property negates calculation of a cystatin C clearance using urine concentrations. The use of serum cystatin C to approximate eGFR is based on the same logic as the use of blood urea nitrogen and creatinine, but because it does not return to the bloodstream and is not secreted, the eGFR obtained may be more reflective of actual renal filtration function.
Endothelial cells, podocytes, mesangial cells, and the glomerular basement membrane are all components of the glomerular membrane and are important for its function. Properties of endothelial cells and their surface layer, the glomerular basement membrane, and podocytes account for variations in glomerular permeability and determine the restriction of solutes based on size, charge, and shape. The glomerular barrier is highly size-selective and chargeselective in qualitative agreement with the classical studies performed 30 years ago. The cellular components are the key players in restricting solute transport, whereas the glomerular basement membrane is responsible for most of the resistance to water flow across the glomerular barrier. The sieving coefficient of a solute is a measure of its transport rate in relation to that of water. Interactions between the particle and the wall are mediated by viscous stresses and pressure variations in the fluid. Such hydrodynamic interactions also cause the velocity of a freely suspended particle to deviate from the mean fluid velocity. The finite size of the particle limits the positions that its center can occupy, bringing steric considerations into the calculation of clearance from the blood pool into the urinary space. Activation of the renin-angiotensin system Advanced liver disease *The impact of some factors on creatinine levels is specific to certain methods of creatinine measurement. 
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(RAS) works to increase intraglomerular pressure and thus increase the filtration of creatinine in the setting of normal renal function. Animal studies have shown that the reduction in angiotensin II caused by the initiation of RAS blockers reduces efferent arteriolar pressure and thus reduces intraglomerular pressure by reducing the transcapillary hydrostatic pressure along the glomerular capillary. 15 In addition, there is a small reduction in tubular secretion of creatinine into the urinary space and an enhanced proximal tubular reabsorption. These mechanisms may explain the predictable Ϸ15% to 30% rise in serum creatinine in patients taking RAS blockers. It is conceivable that creatinine and cystatin C have differing permselectivity functions according to the changes in intraglomerular pressure. The relative size of creatinine is sufficiently small for it to have a high sieving coefficient and, therefore, would have a reduction in filtration in response to a drop in intraglomerular pressure (Figure 3) . 16 Cystatin C, a larger-sized protein, is probably situated at a different location on the sieving function curve and is expected to be influenced less by either an increase or reduction in intraglomerular pressure (Figure 3 ). 17 Thus, it is conceivable that cystatin C is a better indicator of renal filtration function during perturbations of the RAS from early LV dysfunction or use of RAS blocking agents. Sebekova et al 18 studied 12 newly diagnosed individuals with nondiabetic kidney disease (tubulointerstitial nephritis, nϭ8; glomerulonephritis, nϭ2; polycystic kidney disease, nϭ2) and impaired renal function who were subsequently treated with 5 mg daily ramipril (angiotensin-converting enzyme inhibitor) for 2 months. Changes from baseline to follow-up of 1.93 to 1.91 mg/dL for serum creatinine and 1.68 to 1.65 mg/L of cystatin C were found, whereas measured creatinine clearance decreased slightly from 0.72 to 0.76 mL/s, suggesting no differential effect when creatinine clearance is unchanged. 18 In a study by Watanabe et al, 30 patients with nondiabetic hypertension were treated with valsartan for 3 months. Cystatin C decreased (0.63Ϯ0.31 mg/L to 0.52Ϯ0.27 mg/L, Pϭ0.015) but not serum creatinine (0.75Ϯ0.15 mg/dL to 0.74Ϯ0.18 mg/dL, Pϭ0.712). In addition, the renal resistive index by Doppler ultrasonography was reduced, suggesting differential changes in renal filtration of creatinine and cystatin C when treated with a RAS blocker, which reduced intraglomerular pressure. 19 In accordance with these studies, eGFR derived from cystatin C equations is more accurate than eGFR from creatinine equations when a reference standard such as iohexol clearance is measured; however, none specifically compared the two with and without RAS blockers. 11, 20, 21 Finally, cystatin C may be an upregulated and active protein in cardiac remodeling. Cystatin C works to inhibit the activity of cathepsins, which are cysteine proteases that degrade the extracellular matrix proteins via elastolytic and collagenolytic activity. LV remodeling is a complex interaction of matrix assembly and degradation closely regulated by these proteins. Cheng et al 22 have demonstrated increased myocardial cathepsins and cystatin C in rats and humans with LV hypertrophy caused by hypertension. In the early stages of LV remodeling and hypertrophy, cystatin C levels may be elevated, potentially indicating preclinical cardiac disease with or without any renal condition.
In summary, cystatin C is an approved marker that can be used in the calculation of eGFR and may give a truer reflection of eGFR in patients where there is dysregulation of the RAS, either with early LV dysfunction or treatment with RAS blocking drugs. Furthermore, cystatin C may be uniquely intimating early disease of both the heart and the kidneys and, therefore, be a superior prognostic marker to serum creatinine or creatinine-based eGFR as an indicator of renal filtration function.
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Figure 3.
Theoretical sieving coefficient for creatinine and cystatin C at the glomerulus, according to the neutral charge for both and the differing molecular size. As pressure rises in the glomerulus, the filtration of the smaller creatinine molecule is increased, whereas the filtration of the larger cystatin C is relatively unchanged, because it is on a lower portion of the sieving coefficient curve. Adapted from reference 16.
